Abbott LaboratoriesABT
± MixedCapitalrelevance
Article previews upcoming Q2 2026 earnings report with mixed segment trends; no actual results yet.
Impact on stocks 1
Biotech & Genomic Medicine
Abbott LaboratoriesAbbott will report second-quarter 2026 financial results on Thursday, July 16, 2026, before the market opens, with investors watching whether strength in Medical Devices and the newly added oncology diagnostics business can offset softness in Nutrition and Rapid/Molecular Diagnostics. In the first quarter of 2026, Abbott reported net sales of $11.16 billion, up 7.8% from $10.36 billion a year earlier, while adjusted diluted EPS rose 6% to $1.15. Medical Devices sales grew 13.2% on a reported basis, Diagnostics rose 6.1% supported by the Exact Sciences acquisition completed on March 23, 2026, but Nutrition declined 6% due to lower volumes and pricing resets. For the second quarter, Abbott projects adjusted EPS of $1.25 to $1.31, compared to $1.26 in the prior-year period, and full-year 2026 adjusted EPS of $5.38 to $5.58 including $0.20 dilution from the Exact Sciences deal. The stock closed Monday at $92.11, down 1.94%, and traded at $91.58 in pre-market activity.
Abbott LaboratoriesArticle previews upcoming Q2 2026 earnings report with mixed segment trends; no actual results yet.